These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27549176)

  • 1. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma.
    Overman MJ; Soifer HS; Schueneman AJ; Ensor J; Adsay V; Saka B; Neishaboori N; Wolff RA; Wang H; Schnabel CA; Varadhachary G
    BMC Cancer; 2016 Aug; 16(1):668. PubMed ID: 27549176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma.
    Schueneman A; Goggins M; Ensor J; Saka B; Neishaboori N; Lee S; Maitra A; Varadhachary G; Rezaee N; Wolfgang C; Adsay V; Wang H; Overman MJ
    Br J Cancer; 2015 Jun; 113(1):64-8. PubMed ID: 25989273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumors of the ampulla of vater: histopathologic classification and predictors of survival.
    Carter JT; Grenert JP; Rubenstein L; Stewart L; Way LW
    J Am Coll Surg; 2008 Aug; 207(2):210-8. PubMed ID: 18656049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
    Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
    Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
    Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
    [No Abstract]   [Full Text] [Related]  

  • 6. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
    Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
    Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic characterization and clinical outcome in ampullary adenocarcinoma.
    Asano E; Okano K; Oshima M; Kagawa S; Kushida Y; Munekage M; Hanazaki K; Watanabe J; Takada Y; Ikemoto T; Shimada M; Suzuki Y;
    J Surg Oncol; 2016 Jul; 114(1):119-27. PubMed ID: 27132476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the DPC4 tumor suppressor gene in adenocarcinoma of the ampulla of Vater: analysis of 140 cases.
    McCarthy DM; Hruban RH; Argani P; Howe JR; Conlon KC; Brennan MF; Zahurak M; Wilentz RE; Cameron JL; Yeo CJ; Kern SE; Klimstra DS
    Mod Pathol; 2003 Mar; 16(3):272-8. PubMed ID: 12640108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients.
    Vincenzi B; Santini D; Perrone G; Russo A; Adamo V; Rizzo S; Castri F; Antinori A; Alloni R; Crucitti PF; Morini S; Rabitti C; Vecchio FM; Magistrelli P; Coppola R; Tonini G
    Ann Oncol; 2009 Jan; 20(1):78-83. PubMed ID: 18689862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.
    Schultz NA; Werner J; Willenbrock H; Roslind A; Giese N; Horn T; Wøjdemann M; Johansen JS
    Mod Pathol; 2012 Dec; 25(12):1609-22. PubMed ID: 22878649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
    Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
    J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater.
    Chang DK; Jamieson NB; Johns AL; Scarlett CJ; Pajic M; Chou A; Pinese M; Humphris JL; Jones MD; Toon C; Nagrial AM; Chantrill LA; Chin VT; Pinho AV; Rooman I; Cowley MJ; Wu J; Mead RS; Colvin EK; Samra JS; Corbo V; Bassi C; Falconi M; Lawlor RT; Crippa S; Sperandio N; Bersani S; Dickson EJ; Mohamed MA; Oien KA; Foulis AK; Musgrove EA; Sutherland RL; Kench JG; Carter CR; Gill AJ; Scarpa A; McKay CJ; Biankin AV
    J Clin Oncol; 2013 Apr; 31(10):1348-56. PubMed ID: 23439753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers.
    Kwon MJ; Kim JW; Jeon JY; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Min KW; Choe JY; Lee HK
    Pathol Res Pract; 2017 Apr; 213(4):381-388. PubMed ID: 28214200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater.
    Schiergens TS; Reu S; Neumann J; Renz BW; Niess H; Boeck S; Heinemann V; Bruns CJ; Jauch KW; Kleespies A
    Surgery; 2015 Jul; 158(1):151-61. PubMed ID: 25819575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
    Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
    JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
    Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
    Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors of Long-term Survival Following Radical Resection for Ampullary Carcinoma.
    Vilhordo DW; Gregório C; Valentini DF; Edelweiss MIA; Uchoa DM; Osvaldt AB
    J Gastrointest Cancer; 2021 Sep; 52(3):872-881. PubMed ID: 32808236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predictive of survival in ampullary carcinoma.
    Howe JR; Klimstra DS; Moccia RD; Conlon KC; Brennan MF
    Ann Surg; 1998 Jul; 228(1):87-94. PubMed ID: 9671071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical Classification of Ampullary Carcinomas: Critical Reappraisal Fails to Confirm Prognostic Relevance for Recently Proposed Panels, and Highlights MUC5AC as a Strong Prognosticator.
    Xue Y; Reid MD; Balci S; Quigley B; Muraki T; Memis B; Xia J; Hacihasanoglu E; Bedolla G; Pehlivanoglu B; Kim GE; Tajiri T; Ohike N; Aneja R; Krasinskas AM; Adsay V
    Am J Surg Pathol; 2017 Jul; 41(7):865-876. PubMed ID: 28505002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ampullary adenocarcinoma - differentiation matters.
    Schirmacher P; Büchler MW
    BMC Cancer; 2008 Sep; 8():251. PubMed ID: 18761739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.